BH3I-1

• CAT Number: I003045
• CAS Number: 300817-68-9
• Molecular Formula: C₁₅H₁₄BrNO₃S₂
• Molecular Weight: 400.31
• Purity: ≥95%
• Target: Bcl-2 Family
• Solubility: DMSO: ≥ 3.9 mg/mL
• Storage: 2-8°C
• IUPAC Name: 2-[(5E)-5-[(4-bromophenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methylbutanoic acid
• InChI: InChI=1S/C15H14BrNO3S2/c1-8(2)12(14(19)20)17-13(18)11(22-15(17)21)7-9-3-5-10(16)6-4-9/h3-8,12H,1-2H3,(H,19,20)/b11-7+
• InChIKey: COHIEJLWRGREHV-YRNVUSSQSA-N
• SMILES: CC(C)C(C(=O)O)N1C(=O)C(=CC2=CC=C(C=C2)Br)SC1=S

BH3I-1（Cat No.:I003045） is an antagonist of the Bcl-2 family of proteins, known for its ability to inhibit the binding of the Bak BH3 peptide to Bcl-xL. It exhibits a Ki value of 2.4±0.2 μM for this interaction. Additionally, BH3I-1 has a dissociation constant (Kd) of 5.3 μM for the interaction between p53 and murine double minute 2 (mDM2), an important interaction involved in regulating the activity of the tumor suppressor protein p53. BH3I-1’s ability to disrupt these protein-protein interactions makes it a valuable tool for studying and potentially modulating apoptotic pathways and p53-mediated responses.

Reference

1:Profiling small molecule inhibitors against helix-receptor interactions: the Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2. Porter JR, Helmers MR, Wang P, Furman JL, Joy ST, Arora PS, Ghosh I.Chem Commun (Camb). 2010 Nov 14;46(42):8020-2. doi: 10.1039/c0cc02969f. Epub 2010 Sep 20. PMID: 20856941 Free PMC Article2:Enhancement of radiation sensitivity with BH3I-1 in non-small cell lung cancer. Roa W, Chen H, Alexander A, Gulavita S, Thng J, Sun XJ, Petruk K, Moore R.Clin Invest Med. 2005 Apr;28(2):55-63. PMID: 15909480